cvot tirzepatide SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized π« EASD 2025: Tirzepatide (SURPASS-CVOT)
Description
Our clinical team oversees your entire journey, from the initial consultation to ongoing progress monitoring, to ensure your safety and success
Untreated OSA still puts you at high risk for stroke, hypertension, and chronic fatigue
Other Important Foods on a GLP-1 In addition to high-protein foods for GLP-1 users , its also important to focus on hydration, fiber, and nutrient-rich produce
But it can affect how your body responds to thyroid medication in two ways: Increased medication absorption: Zepbound slows down how quickly your stomach empties
